Cargando…

KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study

KRAS mutation is a confirmed predictive biomarker for anti-EGFR monoclonal antibody therapy response for metastatic colorectal cancer. However, its prognosis impact and the predictive potential for first-line standard chemotherapy remains unclear. On the other hand, V600E mutation is the most freque...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garcia-Carbonero, Nuria, Martinez-Useros, Javier, Li, Weiyao, Orta, Alberto, Perez, Nuria, Carames, Cristina, Hernandez, Tatiana, Moreno, Irene, Serrano, Gloria, Garcia-Foncillas, Jesus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016634/ https://www.ncbi.nlm.nih.gov/pubmed/31952366 http://dx.doi.org/10.3390/cells9010219

Ejemplares similares

New Hope for Pancreatic Ductal Adenocarcinoma Treatment Targeting Endoplasmic Reticulum Stress Response: A Systematic Review
por: Garcia-Carbonero, Nuria, et al.
Publicado: (2018)

The Clinical Significance of PIWIL3 and PIWIL4 Expression in Pancreatic Cancer
por: Li, Weiyao, et al.
Publicado: (2020)

A Novel PiRNA Enhances CA19-9 Sensitivity for Pancreatic Cancer Identification by Liquid Biopsy
por: Li, Weiyao, et al.
Publicado: (2022)

UNR/CSDE1 Expression Is Critical to Maintain Invasive Phenotype of Colorectal Cancer through Regulation of c-MYC and Epithelial-to-Mesenchymal Transition
por: Martinez-Useros, Javier, et al.
Publicado: (2019)

The Prognosis Value of PIWIL1 and PIWIL2 Expression in Pancreatic Cancer
por: Li, Weiyao, et al.
Publicado: (2019)

Oxidative Stress: A New Target for Pancreatic Cancer Prognosis and Treatment
por: Martinez-Useros, Javier, et al.
Publicado: (2017)

Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer
por: Ntavatzikos, Anastasios, et al.
Publicado: (2017)

KRAS mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients
por: GUTIÉRREZ, CRISTINA, et al.
Publicado: (2013)

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
por: Borrero-Palacios, A., et al.
Publicado: (2019)

BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy
por: Li, Zi-Nan, et al.
Publicado: (2020)

Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation
por: Huang, Chi-Jung, et al.
Publicado: (2016)

KRAS, NRAS, and BRAF mutations in plasma cell myeloma at a single Korean institute
por: Kim, Yonggoo, et al.
Publicado: (2020)

Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
por: Borrero-Palacios, A., et al.
Publicado: (2019)

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2016)

Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer
por: Aguilera, Oscar, et al.
Publicado: (2016)

Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience
por: Baltruškevičienė, Edita, et al.
Publicado: (2016)

Obesity and colorectal cancer: molecular features of adipose tissue
por: Martinez-Useros, Javier, et al.
Publicado: (2016)

The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer
por: Martinez-Useros, Javier, et al.
Publicado: (2016)

Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis?
por: Martinez-Useros, Javier, et al.
Publicado: (2016)

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
por: Guedes, Joana G, et al.
Publicado: (2013)

KRAS and BRAF Concomitant Mutations in a Patient with Metastatic Colon Adenocarcinoma: An Interesting Case Report
por: Cafiero, Concetta, et al.
Publicado: (2020)

TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer
por: Ntavatzikos, Anastasios, et al.
Publicado: (2019)

KRAS and BRAF genotyping of synchronous colorectal carcinomas
por: GIANNINI, RICCARDO, et al.
Publicado: (2014)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
por: Gattenlöhner, S., et al.
Publicado: (2009)

KRAS, NRAS, BRAF, HER2 and Microsatellite Instability in Metastatic Colorectal Cancer – Practical Implications for the Clinician
por: Afrăsânie, Vlad-Adrian, et al.
Publicado: (2019)

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
por: Bożyk, Aleksandra, et al.
Publicado: (2021)

KRAS and BRAF somatic mutations in colonic polyps and the risk of metachronous neoplasia
por: Juárez, Miriam, et al.
Publicado: (2017)

DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer
por: Martinez-Useros, Javier, et al.
Publicado: (2014)

Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer – a single institution retrospective analysis
por: Rebersek, Martina, et al.
Publicado: (2011)

Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy
por: del Puerto-Nevado, L, et al.
Publicado: (2014)

Sensitive High-Resolution Melting Analysis for Screening of KRAS and BRAF Mutations in Iranian Human Metastatic Colorectal Cancers
por: Niya, Mohammad Hadi Karbalaie, et al.
Publicado: (2016)

Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer
por: Franczak, Claire, et al.
Publicado: (2020)

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2009)

The Match between Molecular Subtypes, Histology and Microenvironment of Pancreatic Cancer and Its Relevance for Chemoresistance
por: Martinez-Useros, Javier, et al.
Publicado: (2021)

Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
por: Madoz-Gúrpide, Juan, et al.
Publicado: (2015)

Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma
por: Stefanius, Karoliina, et al.
Publicado: (2011)

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

Mitochondrial Respiration in KRAS and BRAF Mutated Colorectal Tumors and Polyps
por: Rebane-Klemm, Egle, et al.
Publicado: (2020)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vk1usj0gv3l0bc0daric6er2js